Kumar Neil sold $2.9M of BBIO

Kumar Neil (Chief Executive Officer) sold 34,980 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $82.53 ($81.15–$83.77, $2.89M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Aug 20, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BBIO
Bearish
medium confidence
Mentioned
$BBIO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIOBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a negative signal, though it could simply be a planned liquidity event.

02

Market read

Insider sales are closely monitored; this filing provides fresh data for traders evaluating BBIO.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑20

Background

Form 4 filing reveals a CEO's open‑market sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$BBIOBearishMedium confidence
Context

CEO Kumar Neil sold 34,980 shares for $2.9M via a 10b5-1 plan, reducing his stake to 243,327 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Insider sales by a CEO are watched closely; the $2.9M amount is material for a mid‑cap biotech, but not large enough to trigger a sharp move.

Market effects

May raise concerns for biotech sector investors tracking insider activity.

Limited to US biotech investors; no broader regional effect.

Minimal global impact.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • BridgeBio Pharma, Inc.

    Biotech firm listed on Nasdaq (BBIO).

  • Kumar Neil

    Chief Executive Officer of BridgeBio Pharma.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.